# Acute postoperative pain in adults

# Critical elements for pain reporting in systematic reviews & meta-analyses



This guide aims at helping those performing systematic reviews in adults (especially Cochrane Reviews) to avoid known pitfalls for acute pain. Each point is based firmly on evidence from pain analyses.

# STUDY DESIGN Elements that strongly affect efficacy



#### Randomisation

Is the study randomised?

Include studies where the words 'random', 'randomly', or 'randomisation' are explicit



Sensitivity recommended



Non-randomised studies can overestimate efficacy





#### **Double-blinding** Is the study double blind?

Include studies where the word 'double-blinding' is explicit, or where neither the care giver nor the patient could identify the treatment being assessed



Sensitivity analysis recommended



Non-double-blinded studies can overestimate efficacy





# Pain measuring

Who measures pain?

Include studies where participants are adults, able to communicate & measure their own pain



Pain measurements by someone other than the person with pain can be underestimated

MEASURING POSTOP PAIN Slide set 2



#### Level of initial pain

Is pain before treatment moderate or severe?

Include studies where pain levels are at least moderate, to ensure sensitivity



Sensitivity analysis recommended



Where initial pain is not at least moderate in intensity there is a lack of sensitivity, and analgesic effects can be underestimated



**MEASURING POSTOP PAIN** Slide set 2

**LESSONS IN** PRACTICE Slide set 7



#### Diagnostic criteria

Is the pain condition defined with standard or specific criteria? Check for consistency across studies & report inconsistencies



Response of pain to analgesic interventions can vary according to the pain condition studied (drug vs placebo)



# Withdrawals

How does the study deal with withdrawals in data analysis? BOCF (baseline-observation-carried-forward) is the most conservative



Sensitivity analysis recommended when using different methods

Common methods such as "completers" or "per protocol" analysis, or imputing missing data using LOCF can overestimate treatment effects



# STUDY OUTCOMES Important considerations



**OUTCOMES** Slide set 3



#### Averages

Pain scores or change in pain

Responder analyses are preferable and typically bimodal – good/very good or poor/very poor



Average pain scores can be misleading if treatment outcomes are not normally distributed



### Pain reduction

Number of persons responding to pain reduction

Measuring end points can be useful – for example, the number/ proportion of participants with ≥50% pain intensity reduction, ≥50% pain relief, numbers of persons with no worse than mild pain



### Analgesia duration

Measures relating to the duration of analgesia

Examples include -

how long before additional analgesia is given, percentage of participants remedicating by a particular time



### Analgesic consumption

Measures relating to analgesic consumption

Desirable outcome –

Reduced postoperative analgesic consumption resulting from a perioperative intervention



Analgesic consumption postoperatively has a highly skewed distribution, differences of a few mg in mean opioid consumption may be statistically significant, but of no clinical value



#### Adverse events

Significant adverse events

Consider the information of how adverse events were measured and categorised/ classified within the study as this can substantially impact the results



Post-operative nausea & vomiting can be distressing and time consuming



#### Hospital stay **Duration of hospital stay**

Use this outcome with caution



Few studies give sufficient detail to be certain about the robustness of this outcome

# STUDY MAGNITUDE Caution for possible bias



#### Study size

Number of participants per treatment arm

Prefer intermediate (50-199 participants per treatment arm) or large (≥200 participants per treatment arm) size studies



Sensitivity analysis recommended to explore the impact of including small studies

Small studies (<50 participants per treatment arm) can overestimate treatment effects,

especially in pain

Slide set 5 **LESSONS IN PRACTICE** Slide set 7

STUDY SIZE



#### Publication bias

Is there susceptibility to publication bias?

The risk of publication bias increases where small studies dominate the evidence



Small numbers of small studies & minimal clinical effectiveness show high susceptibility to publication bias





